Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 120-126

  Tsuruta, Yuki ^a   Okano, Kazuhiro ^a   Kikuchi, Kan ^a   Tsuruta, Yukio ^b   Akiba, Takashi ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Tsuruta Clinic   (Japan)

Author keywords

Alkaline phosphatase; Bone mineral density; Cinacalcet; CKD MBD; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; INTACT PARATHYROID HORMONE; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; FEMUR NECK; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; MALE; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; CALCIMIMETIC AGENTS; FEMALE; FEMUR NECK; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; REGRESSION ANALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874108937     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0665-8     Document Type: Article

References (27)

1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945-53.
2. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol. 2007;11:261-8.
3. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17:3223-32.
4. Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18:282-6.
5. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396-9.
6. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115-21.
7. Yajima A, Inaba M, Tominaga Y, Ito A. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int. 2008;74:775-81.
8. Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:3845-51.
9. Chou FF, Chen JB, Lee CH, Chen SH, Sheen-Chen SM. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg. 2001;136:1064-8.
10. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol. 2007;18:2401-7.
11. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516-25.
12. de Francisco AL, Izquierdo M, Cunningham J, Piñera C, Palomar R, Fresnedo GF, et al. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant. 2008;23:2895-901.
13. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15:2579-87.
14. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67:467-76.
15. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1232-7.
16. Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation. 2008;86:413-7.
17. Toro Prieto FJ, Bernal Blanco G, Navarro García M, Cabello Chaves V, Garcíajiménez R, Pereira Palomo P, Gentil Govantes MA. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc. 2009;41:2144-7.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.
19. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800-7.
20. Chattopadhyay N, Yano S, Tfelt-Hansen J, Rooney P, Kanuparthi D, Bandyopadhyay S, et al. Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology. 2004;145:3451-62.
21. Miller MA, Chin J, Miller SC, Fox J. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 1998;23:257-66.
22. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998;53:448-53.
23. El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2011;15:547-55.
24. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793-800.
25. Yajima A, Inaba M, Ogawa Y, Tominaga Y, Tanizawa T, Inou T, Otsubo O. Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant. 2007;22:1645-57.
26. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, KRN1493 Study Group. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2009;29:230-6.
27. Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, Rakugi H, Isaka Y. Usefulness of bone resorption markers in hemodialysis patients. Bone. 2009;45(Suppl 1):S19-25.